Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040
Journal
Annals of oncology : official journal of the European Society for Medical Oncology
Date Issued
2024-01-25
Author(s)
El-Khoueiry, A B
Trojan, J
Meyer, T
Yau, T
Melero, I
Kudo, M
Kim, T-Y
Choo, S-P
Kang, Y-K
Yeo, W
Chopra, A
Soleymani, S
Yao, J
Neely, J
Tschaika, M
Welling, T H
Sangro, B
Abstract
Patients with advanced hepatocellular carcinoma (aHCC) have a poor prognosis and high mortality. Nivolumab monotherapy demonstrated clinical benefit with an acceptable safety profile in patients with aHCC in the CheckMate 040 study. Five-year follow-up of the sorafenib-naive and sorafenib-experienced groups of CheckMate 040 is presented here.
Subjects
advanced hepatocellular carcinoma; checkpoint inhibitor; nivolumab; sorafenib
Type
journal article